Pharmacological rescue of Ras signaling, GluA1-dependent synaptic plasticity, and learning deficits in a fragile X model
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Fragile X syndrome, caused by the loss of Fmr1 gene function, is the most common form of inherited mental retardation, with no effective treatment. Using a tractable animal model, we investigated mechanisms of action of a few FDA-approved psychoactive drugs that modestly benefit the cognitive performance in fragile X patients. Here we report that compounds activating serotonin (5HT) subtype 2B receptors (5HT 2B-Rs) or dopamine (DA) subtype 1-like receptors (D 1-Rs) and/or those inhibiting 5HT 2A-Rs or D 2-Rs moderately enhance Ras–PI3K/PKB signaling input, GluA1-dependent synaptic plasticity, and learning in Fmr1 knockout mice. Unexpectedly, combinations of these 5HT and DA compounds at low doses synergistically stimulate Ras–PI3K/PKB signal transduction and GluA1-dependent synaptic plasticity and remarkably restore normal learning in Fmr1 knockout mice without causing anxiety-related side effects. These findings suggest that properly dosed and combined FDA-approved psychoactive drugs may effectively treat the cognitive impairment associated with fragile X syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 2×
“Because developing a new drug takes ;8– 15 years (>13 years for neurological disorders) and costs ;$800 million–$1800 million (Adams and Brantner 2010; Paul et al. 2010), any effective treatment for fragile X 2014 Lim et al. This article is distributed exclusively by Cold Spring Harbor Laboratory…”
BackgroundFMRP Stalls Ribosomal Translocation on mRNAs Linked to Synaptic Function and Autism
Darnell, J. C., Van Driesche, S. J., Zhang, C., Hung, K. Y. S., Mele, A., Fraser, C. E., Stone, E. F., Chen, C., Fak, J. J., Chi, S. W., et al. (2011) · Cell · doi:10.1016/j.cell.2011.06.013 · Cited by 2,072 · cited 1×
“This synergistic effect can take place within 1 d after application or administration of the 5HTand DA compounds, which rules out the contribution from the indirect effects of 5HT and DA compounds (e.g., changes in mood/anxiety) that take $2 wk to develop (Wong and Licinio 2001; David et al. 2010).”
BackgroundHayashi, Y., Shi, S.-H., Esteban, J. A., Piccini, A., Poncer, J.-C., & Malinow, R. (2000) · Science · doi:10.1126/science.287.5461.2262 · Cited by 1,524 · cited 1×
“We monitored the GluA1dependent plasticity by expressing the GFP-tagged GluA1 (GluA1-GFP), which is an ‘‘electrophysiologically tagged’’ or rectified channel (Hayashi et al. 2000), in CA1 neurons of wild-type and Fmr1 knockout mice.”
MethodThe developmental role of serotonin: news from mouse molecular genetics
Gaspar, P., Cases, O., & Maroteaux, L. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1256 · Cited by 1,297
Roth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155 · cited 2×
“Psychoactive drugs, particularly those targeting PI3K/ PKB signaling, are commonly used to treat a number of mental and psychiatric disorders, including autism spectrum disorders, bipolar disorder, attention deficit/hyperactivity disorder, depression, and schizophrenia (Roth et al. 2004; Beaulieu 2012).”
BackgroundBrown, V., Jin, P., Ceman, S., Darnell, J. C., O'Donnell, W. T., Tenenbaum, S. A., Jin, X., Feng, Y., Wilkinson, K. D., Keene, J. D., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00568-2 · Cited by 1,109
Synaptic AMPA receptor plasticity and behavior
Kessels, H. W., & Malinow, R. (2009) · Neuron · doi:10.1016/j.neuron.2009.01.015 · Cited by 993 · cited 1×
“Spontaneous synaptic activity in cultured slices does not drive GluA1containing AMPA-Rs into synapses but does so in the presence of histamine (Qin et al. 2005; McCormack et al. 2006; Kessels and Malinow 2009); thus, histamine was included in all in vitro trafficking experiments.”
BackgroundVyazovskiy, V. V., Cirelli, C., Pfister-Genskow, M., Faraguna, U., & Tononi, G. (2008) · Nature Neuroscience · doi:10.1038/nn2035 · Cited by 837 · cited 1×
“…in saline, and saline alone was tested as controls, and their dosages were estimated based on the published data (PuglisiAllegra and Cabib 1988; Costall and Naylor 1995; Kennett et al. 1997; O’Dell et al. 2000; Usiello et al. 2000; Wang et al. 2008) and dose response curves (cf. Supplemental Fig.”
MethodImportance of AMPA Receptors for Hippocampal Synaptic Plasticity But Not for Spatial Learning
Zamanillo, D., Sprengel, R., Hvalby, Ø., Jensen, V., Burnashev, N., Rozov, A., Kaiser, K. M. M., Köster, H. J., Borchardt, T., Worley, P., et al. (1999) · Science · doi:10.1126/science.284.5421.1805 · Cited by 791 · cited 2×
“…exhibit a selective impairment in associative learning (Maes et al. 1994; Paradee et al. 1999; Van Dam et al. 2000; Frankland et al. 2004; Zhao et al. 2005; Hayashi et al. 2007; Lanfranchi et al. 2009), an exact phenocopy of GluA1 knockout mice (Zamanillo et al. 1999; Schmitt et al. 2004, 2005).”
BackgroundPostsynaptic receptor trafficking underlying a form of associative learning
Rumpel, S., LeDoux, J., Zador, A., & Malinow, R. (2005) · Science · doi:10.1126/science.1103944 · Cited by 775
Cited by
Advancing the understanding of autism disease mechanisms through genetics
de la Torre-Ubieta, L., Won, H., Stein, J. L., & Geschwind, D. H. (2016) · Nature Medicine · doi:10.1038/nm.4071 · Cited by 827
Excitation/Inhibition Imbalance in Animal Models of Autism Spectrum Disorders
Lee, E., Lee, J., & Kim, E. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.05.011 · Cited by 468
Barnes, N. M., Ahern, G. P., Becamel, C., Bockaert, J., Camilleri, M., Chaumont-Dubel, S., Claeysen, S., Cunningham, K. A., Fone, K. C., Gershon, M., et al. (2021) · Pharmacological Reviews · doi:10.1124/pr.118.015552 · Cited by 263
Autism and the synapse: emerging mechanisms and mechanism-based therapies
Ebrahimi-Fakhari, D., & Sahin, M. (2015) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000186 · Cited by 167
“Dopamine-dependent long-term potentiation (LTP) is diminished in Fmr1deficient mice, and dopamine-agonist treatment can improve hyperactivity and motor symptoms in FXS patients [26,31,32].”
BackgroundThe Brain-Enriched MicroRNA miR-9-3p Regulates Synaptic Plasticity and Memory
Sim, S.-E., Lim, C.-S., Kim, J.-I., Seo, D., Chun, H., Yu, N.-K., Lee, J., Kang, S. J., Ko, H.-G., Choi, J.-H., et al. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.0630-16.2016 · Cited by 116
Self-citationTherapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and Back
Gross, C., Hoffmann, A., Bassell, G. J., & Berry-Kravis, E. M. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0355-9 · Cited by 105
Serotonin, neural markers, and memory
Meneses, A. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00143 · Cited by 90
“…Ras-PI3K/PKB signaling input, GluA1-dependent synaptic plasticity and learning in Fmr1 KO mice; without causing anxiety related side effects Lim et al., 2014 5-HT2B receptor expression Htr2B −/− mice, as shown by deficits in sensorimotor gating, in selective attention, in…”
BackgroundInfluentialWang, G., Bochorishvili, G., Chen, Y., Salvati, K. A., Zhang, P., Dubel, S. J., Perez-Reyes, E., Snutch, T. P., Stornetta, R. L., Deisseroth, K., et al. (2015) · Genes & Development · doi:10.1101/gad.260869.115 · Cited by 53
“2009) mice bred congenically on the C57BL/6 background, following our previous studies (Qin et al. 2005; Lim et al. 2014).”
BackgroundMethodInfluentialSelf-citationD’Incal, C., Broos, J., Torfs, T., Kooy, R. F., & Vanden Berghe, W. (2022) · Cells · doi:10.3390/cells11081325 · Cited by 29
“…(Sharma et al., 2010) Increased Human FXS lymphoblastoidcell cultures (Gross and Bassell, 2012) Decreased Fmr1 knock-out mousehippocampal cultures (Lim et al., 2014) Increased Fmr1 knock-out mouseprimary hippocampal cultures (Ding et al., 2020) Increased Human iPSC derived neuralFXS model (Raj et…”
BackgroundResultInfluential
Metadata
- Authors
- Lim, C.-S., Hoang, E. T., Viar, K. E., Stornetta, R. L., Scott, M. M., & Zhu, J. J.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2014-02-01
- Volume
- 28
- Issue
- 3
- Pages
- 273-289
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2119262860
- Cited by
- 56
- References
- 33
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.